+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 40Years - 85Years
All Genders
ID07402551

Randomized, Double-Blind Study to Assess RC1416 Injection Versus Placebo in Adults Aged 40-85 With Moderate to Severe Chronic Obstructive Pulmonary Disease

Led by Nanjing RegeneCore Biotech Co., Ltd. · Updated on 2026-09-08

180

Participants Needed

46

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease COPD. This phase II, multicenter, randomized, double-blind, placebo-controlled study aims to assess important clinical outcomes such as the annual rate of moderate or severe COPD exacerbations and changes in lung function measured by forced expiratory volume in 1 second FEV1 over a 52-week treatment period. Participants will receive either RC1416 injection or a placebo by subcutaneous injection once every two weeks for a total treatment duration of 52 weeks. The study also evaluates changes in biomarkers including fractional exhaled nitric oxide FeNO, total immunoglobulin E IgE, eosinophil count, and thymus and activation-regulated chemokine TARC from baseline during treatment. Throughout the study, participants will be closely monitored with assessments focusing on safety, tolerability, pharmacokinetics, immunogenicity, and biomarkers predictive of efficacy. These evaluations occur during the 52-week treatment period, allowing researchers to comprehensively analyze both clinical and biological responses. The total participation duration aligns with the full year of treatment and follow-up assessments.

CONDITIONS

Brief Title

Phase II Study of RC1416 Injection in COPD

Research Team

Y

Yumin Zhou, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here